Last reviewed · How we verify
Botulinum Toxin: Xeomin
Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Botulinum Toxin: Xeomin |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (synaptosome-associated protein) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
Xeomin cleaves SNARE proteins required for acetylcholine vesicle fusion and release at motor nerve terminals. This results in temporary denervation and muscle relaxation. The effect is localized to injected muscles and gradually reverses as new neuromuscular junctions form over 3-4 months.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (aesthetic indication)
- Spasticity
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness
- Eyelid ptosis
- Dry mouth
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation (NA)
- Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum Toxin: Xeomin CI brief — competitive landscape report
- Botulinum Toxin: Xeomin updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI